MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma

M. J.M. van Velzen, S. Derks, N. C.T. van Grieken, N. Haj Mohammad, H. W.M. van Laarhoven

Research output: Contribution to journalReview articleAcademicpeer-review

50 Citations (Scopus)


Gastroesophageal cancers are a major cause of death worldwide and treatment outcomes remain poor. Adequate predictive biomarkers have not been identified. Microsatellite instability (MSI) as a result of mismatch repair deficiency is present in four to twenty percent of gastroesophageal cancers and has been associated with favorable survival outcomes compared to microsatellite stable tumors. This prognostic advantage may be related to immunosurveillance, which may also explain the favorable response to immune checkpoint inhibition observed in MSI high (MSI-H) tumors. The value of conventional cytotoxic treatment in MSI-H tumors is unclear and results on its efficacy range from detrimental to beneficial effects. Here the recent data on MSI as a predictive factor for outcome of gastroesophageal cancer treatment is reviewed.

Original languageEnglish
Article number102024
JournalCancer treatment reviews
Publication statusPublished - 1 Jun 2020


  • Checkpoint inhibition
  • Chemotherapy
  • Gastroesophageal cancer
  • Immunotherapy
  • Microsatellite instability
  • Mismatch repair deficiency

Cite this